MedChemExpress LLC (MCE)
  1. Companies
  2. MedChemExpress LLC (MCE)
  3. Products
  4. MedChemExpress - Model Sofituzumab ...

MedChemExpressModel Sofituzumab vedotin - 1418200-58-4

SHARE
Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer[1].
Most popular related searches

MCE products for research use only. We do not sell to patients.

Sofituzumab vedotin

MCE China:Sofituzumab vedotin

Brand:MedChemExpress (MCE)

Cat. No.HY-P99593

CAS:1418200-58-4

Synonyms:DMUC5754A

Purity:98.72%

Storage:Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping:Shipping with dry ice.

Description:Sofituzumab vedotin (DMUC5754A) is a MMAE-containing anti-MUC16 antibody-drug conjugate (ADC) with a protease-cleavable linker. Sofituzumab vedotin can be used for the research of cancer.

In Vitro:Sofituzumab vedotin (DMUC5754A) is an antibody–drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-labile linker, maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl[2]. Sofituzumab vedotin (3A5-VC-MMAE; 0.1-10000ng/mL; 3 or 5 days) inhibits OVCAR-3 and PC3/MUC16TMlong cells proliferation in a dose-dependent manner[3].

In Vivo:Sofituzumab vedotin (3A5-VC-MMAE; 2 and 2.8 mg/kg; IV; once weekly for 3 or 4 total doses) shows potent anti-tumor activity in MUC16-expressing human OVCAR-3 mouse xenograft models[3].

Hot selling product:AR7  | Belimumab  | Luteolin 7-diglucuronide  | SR1078  | Oleoylethanolamide  | Sulfo-SMCC (sodium)  | Hesperetin  | 5β-Cholanic acid  | Latanoprost  | Carbidopa

Trending products:Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References:

[1]. Manzano A, et al. Antibody-Drug Conjugates: A Promising Novel Therapy for the Treatment of Ovarian Cancer. Cancers (Basel). 2020 Aug 9;12(8):2223.  [Content Brief]

[2]. Liu JF, et al. Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 Nov;27(11):2124-2130.  [Content Brief]

[3]. Chen Y, et al. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models. Cancer Res. 2007 May 15;67(10):4924-32.  [Content Brief]

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world;
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas;
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects;
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services;
•   It has a professional experimental center and strict quality control and verification system;
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products;
•   The biological activity of the products has been verified by the experiments of customers in various countries;
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers;
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world;
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。